Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease

University of Saskatchewan

Status and phase: Completed; Phase 4

Conditions: Asthma; COPD

Treatments: Drug: salbutamol

Study type: Interventional

Funder types: Other

Identifiers

NCT00440245

Bio-REB 06-231

Details and patient eligibility

About

This study will investigate potential differences in how two puffs of salbutamol protects airway smooth muscle from contracting in people with asthma and chronic obstructive pulmonary disease (COPD).

Full description

In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g. salbutamol), prior to methacholine challenge has been shown to shift the dose response curve to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The extent of β2 receptor agonist bronchoprotection in COPD is unknown.

Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed to be due to changes in airway smooth muscle (e.g. hypertrophy, hyperplasia, contractile apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.

The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• asthma or COPD

Exclusion criteria

• asthma and COPD

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

salbutamol

Other group

Description:

There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).

Treatment:

Drug: salbutamol